F2G, Patrick Vink
European biotech F2G, focusing on the development of treatments for life-threatening fungal infections, appointed Patrick Vink as chairman of the board of directors.
Vink has been a member of the biotechnology and pharmaceutical industry for over 30 years, including experience as COO at Cubist Pharmaceuticals, which was acquired by Merck. Prior to his role at Cubist, Vink served as head of global hospital business at Mylan, and head of global biopharmaceuticals at Sandoz.
“During his career, he has been responsible for several successful new product launches and held senior roles overseeing R&D and commercial and technical operations,” Ian Nicholson, CEO of F2G said. “His breadth and depth of experience will be invaluable as we accelerate the development of our lead candidate olorofim as a treatment for rare invasive fungal infections.”
Currently, Vink is on the board of various US and European companies including Acacia Pharma, Targovax, and NMD Pharma.
